DUPIXENT: cost and payments to doctors
What Medicare Part D paid pharmacies for DUPIXENT, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Part D cost for DUPIXENT formulations
Medicare reports DUPIXENT under its specific formulations, which are priced separately.
- dupixent pen$3,826per 30-day fill · 390,688 claims · Dupilumab
- dupixent syringe$3,807per 30-day fill · 131,665 claims · Dupilumab
Paid to pharmacies by Part D plans and patients — not your cost, and not paid to the prescriber. Is this wrong?
Was your doctor paid by Sanofi?
Sanofi reported the most payments naming DUPIXENT. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $185.7M
- Providers
- 82,131
- Transactions
- 1,356,584
- Average per transaction
- $137
The per-transaction average — $137 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 82,131 providers the average total is $2,261, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $103,927,500 | 56.0% |
| Regeneron Healthcare Solutions, Inc. | $72,899,973 | 39.3% |
| Sanofi-aventis U.S. LLC | $4,377,310 | 2.4% |
| Regeneron | $4,029,951 | 2.2% |
| Sanofi US Services Inc. | $442,021 | 0.2% |
| Sanofi Pasteur Inc. | $3,422 | 0.0% |
Other products from Sanofi
The company that reported the most payments naming DUPIXENT also reports against these.